Loading…
← CockpitCompetitor Analysis › 456160.KS G2GBIO, Inc.Open in the cockpit ↗

G2GBIO, Inc.456160.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology
Momentum weak 36
Mkt cap
$416M
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$12.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Close · KRW₩33,600
1D+4.7%
1W-9.6%
1M-9.2%
3M-23.8%
6M-52.5%
YTD-49.9%
1Y-43.3%
ATR %11.9%
52w lowhigh72.9% off high

What G2GBIO does

Employees: 48

G2GBIO at a glance

Size G2GBIO (456160.KS) is a South Korea Health Care company (Biotechnology) with a market value of $416M, the 393rd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩33,600 on 18 Nov 2026.

Performance Over six months the shares fell 52.5%, against -22.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 45.0% over the last twelve months (peer median +4.8%); the operating margin is -2,884.2% (peer median -4.5%).

Valuation It trades at 908.6× enterprise value to sales against a peer median of 4.0× (most expensive of 16).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 78456160.KS 51
Six months, rebased to 100: G2GBIO against the median of its 20 peers (local-currency closes).

G2GBIO financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/a₩423M₩769M₩740M₩241M
Revenue growth—-45%+4%+208%—
Gross profitn/a-₩1.49B-₩1.49B-₩1.35B-₩1.38B
EBITDAn/a-₩10.6B-₩8.93B-₩11.4B-₩9.84B
Net incomen/a-₩12.1B-₩83.3B-₩10.5B₩15.1B
Free cash flown/a-₩14.2B-₩8.55B-₩11.8B-₩14.4B
Capital expendituren/a₩324M₩844M₩970M₩5.68B
Total debt₩44.0B₩7.13B₩115B₩56.3B₩52.8B

Quarterly statements and history in the cockpit →

G2GBIO competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%688163EPRXCADL476830688238688317699833786547671225091167PRTA68809817892480603739300683000710IRLA456160.KS6-month return →1-month return →
Up and to the right = strong over both horizons. G2GBIO is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×500×688163476830688238699825091167456160.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. G2GBIO is the large dot.

G2GBIO competitors and peer comparison

How G2GBIO compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

G2GBIO against its 20 peers (data as of 18 Nov 2026)
Measure456160.KSPeer medianRank in peer set
1-month return-9.2%-14.1%8th highest of 21
6-month return-52.5%-22.0%2nd lowest of 21
Distance from 52-week high-72.9%-41.5%3rd lowest of 21
Revenue growth (TTM)-45.0%+4.8%2nd lowest of 16
Operating margin-2,884.2%-4.5%lowest of 16
EV / Sales908.6×4.0×most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a

Questions

Which companies are G2GBIO's closest peers?
The cockpit's peer set: Shanghai Serum Bio-Technology (688163.SS), Eupraxia Pharmaceuticals (EPRX.TO), Candel Therapeutics (CADL), Rznomics (476830.KS), Shanghai Obio Technology (Group) (688238.SS), Shanghai ZJ Bio-Tech (688317.SS), Edding Genor (6998.HK), Hanx Biopharmaceuticals (Wuhan) (3378.HK).
Is G2GBIO expensive compared with its peers?
On ev / sales it trades at 908.6× against a peer median of 4.0×, most expensive of 16 in its peer set.
How has G2GBIO stock performed?
Over six months to 18 Nov 2026 the shares returned -52.5% against -22.0% for the median peer; over one year -43.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.